Company profile for Aeterna Zentaris

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordis...
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
315 Sigma Drive Summerville, SC 29486
Telephone
Telephone
843-900-3223
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3197504/0/en/COSCIENS-Announces-Exclusive-Distribution-Agreement-with-Wuzhou-Drug-International-for-Macrilen-in-Hainan-Guangdong-Hong-Kong-Macao-Greater-Bay-Area-and-Singapore.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/04/01/3053872/0/en/COSCIENS-Biopharma-Inc-Announces-Receipt-of-Management-Cease-Trade-Order.html

GLOBENEWSWIRE
01 Apr 2025

https://www.globenewswire.com/news-release/2024/08/06/2925576/0/en/Aeterna-Zentaris-Inc-Announces-Name-Change-to-COSCIENS-Biopharma-Inc.html

GLOBENEWSWIRE
07 Aug 2024

https://www.globenewswire.com/news-release/2024/07/16/2914159/0/en/Aeterna-Zentaris-Announces-Results-of-Virtual-2024-Meeting-of-Shareholders.html

GLOBENEWSWIRE
16 Jul 2024

https://www.globenewswire.com/news-release/2024/06/13/2898343/0/en/Aeterna-Zentaris-Announces-Last-Patient-Last-Visit-in-Pivotal-DETECT-Trial-for-the-Diagnosis-of-Childhood-Onset-Growth-Hormone-Deficiency.html

GLOBENEWSWIRE
13 Jun 2024

https://www.globenewswire.com/news-release/2024/06/03/2892323/0/en/Aeterna-Zentaris-and-Ceapro-Complete-Merger-Transaction.html

GLOBENEWSWIRE
03 Jun 2024

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Aeterna Zentaris and get a quotation

Aeterna Zentaris is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of Perifosine bulk offered by Aeterna Zentaris

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty